Laura LOPEZ-GÓMEZ

Dr. Laura LOPEZ-GÓMEZ

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LLLaura LOPEZ-GÓMEZ
Laura LOPEZ-GÓMEZ
AAAlexandra Alcorta
Alexandra Alcorta
Raquel AbaloRaquel Abalo
Raquel Abalo
Cancer chemotherapy has allowed many patients to survive, but not without risks derived from its adverse effects. Drugs, such as 5-fluorouracil, irinotecan, oxaliplatin, methotrexate, and others, as well as different drug combinations trigger intestinal mucositis that may cause or contribute to anorexia, pain, diarrhea, weight loss, systemic infections, and even death. Dysbiosis is a hallmark of chemotherapy-induced intestinal mucositis and diarrhea, and, therefore, strategies aimed at modulating intestinal microbiota may be useful to counteract and prevent those dreadful effects. This narrative review offers an overview of the studies performed to test the efficacy of probiotics and probiotic-like agents against chemotherapy-induced intestinal mucositis and its consequences. Microbiota modulation through the oral administration of different probiotics (mainly strains of Lactobacillus and Bifidobacterium), probiotic mixtures, synbiotics, postbiotics, and paraprobiotics has been tested in different animal models and in some clinical trials. Regulation of dysbiosis, modulation of epithelial barrier permeability, anti-inflammatory effects, modulation of host immune response, reduction of oxidative stress, or prevention of apoptosis are the main mechanisms involved in their beneficial effects. However, the findings are limited by the great heterogeneity of the preclinical studies and the relative lack of studies in immunocompromised animals, as well as the scarce availability of results from clinical trials. Despite this, the results accumulated so far are promising. Hopefully, with the aid of these agents, intestinal mucositis will be less impactful to the cancer patient in the near future.

Verified
Journal Article
Open access
PDF file
AMAlba Montalbán-Rodríguez
Alba Montalbán-Rodríguez
Raquel AbaloRaquel Abalo
Raquel Abalo
LLLaura LOPEZ-GÓMEZ
Laura LOPEZ-GÓMEZ
The brain–gut axis has been identified as an important contributor to the physiopathology of Parkinson’s disease. In this pathology, inflammation is thought to be driven by the damage caused by aggregation of α-synuclein in the brain. Interestingly, the Braak’s theory proposes that α-synuclein misfolding may originate in the gut and spread in a “prion-like” manner through the vagus nerve into the central nervous system. In the enteric nervous system, enteric glial cells are the most abundant cellular component. Several studies have evaluated their role in Parkinson’s disease. Using samples obtained from patients, cell cultures, or animal models, the studies with specific antibodies to label enteric glial cells (GFAP, Sox-10, and S100β) seem to indicate that activation and reactive gliosis are associated to the neurodegeneration produced by Parkinson’s disease in the enteric nervous system. Of interest, Toll-like receptors, which are expressed on enteric glial cells, participate in the triggering of immune/inflammatory responses, in the maintenance of intestinal barrier integrity and in the configuration of gut microbiota; thus, these receptors might contribute to Parkinson’s disease. External factors like stress also seem to be relevant in its pathogenesis. Some authors have studied ways to reverse changes in EGCs with interventions such as administration of Tryptophan-2,3-dioxygenase inhibitors, nutraceuticals, or physical exercise. Some researchers point out that beyond being activated during the disease, enteric glial cells may contribute to the development of synucleinopathies. Thus, it is still necessary to further study these cells and their role in Parkinson’s disease.

4 July 2018 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
LLLaura LOPEZ-GÓMEZ
Laura LOPEZ-GÓMEZ
SDS. Díaz‐Ruano
S. Díaz‐Ruano
RMROCIO GIRON MORENO
ROCIO GIRON MORENO
ALA. E. López‐Pérez
A. E. López‐Pérez
GVG. Vera
G. Vera
Raquel AbaloRaquel Abalo
Raquel Abalo

16 August 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
LLLaura LOPEZ-GÓMEZ
Laura LOPEZ-GÓMEZ
Jose UrangaJose Uranga
Jose Uranga
Polyphenols are plant metabolites with potential anti-inflammatory and anti-proliferative effects, which may be advantageous for disorders like colorectal cancer (CRC). Despite promising in vitro and in vivo evidence, human clinical trials have yielded mixed results. The present study aimed to evaluate the clinical evidence of polyphenols for CRC prevention or treatment. A systematic review was performed according to PRISMA. Based on a PROSPERO registered protocol (CRD42024560044), online databases (PubMed and COCHRANE) were utilized for the literature search. A total of 100 studies articles were initially identified. After reviewing, 12 studies with a low risk of bias were selected, examining the effect of a variety of compounds. Curcumin demonstrated promise in various trials, mainly decreasing inflammatory cytokines, though results varied, and it did not lower intestinal adenomas or improve outcomes after chemotherapy. Neither epigallocatechin gallate nor artepillin C reduced the incidence of adenomas. Finally, fisetin seemed to improve the inflammatory status of patients under chemotherapy (5-fluorouracil). In summary, although certain polyphenols appear to exert some effect, their role in the prevention or treatment of CRC is inconclusive, and more clinical studies under more controlled conditions are needed.

23 June 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
Amaia Iriondo-DeHondAmaia Iriondo-DeHond
Amaia Iriondo-DeHond
FCFresia Santillan Cornejo
Fresia Santillan Cornejo
BGBeatriz Fernández Gómez
Beatriz Fernández Gómez
GVGema Vera
Gema Vera
EGEduardo Guisantes-Batan
Eduardo Guisantes-Batan
Dolores del CastilloDolores del Castillo
Dolores del Castillo
The bioaccessibility, metabolism, and excretion of lipids composing spent coffee grounds (SCGs) were investigated. An analysis of mycotoxins and an acute toxicity study in rats were performed for safety evaluation. Total fat, fatty acids, and diterpenes (cafestol and kahweol) were determined in SCGs and their digests obtained in vitro. A pilot repeated intake study was carried out in Wistar rats using a dose of 1 g SCGs/kg b.w. for 28 days. Fat metabolism was evaluated by analysis of total fat, cholesterol, and histology in liver. The dietary fiber effect of SCGs was measured radiographically. The absence of mycotoxins and toxicity was reported in SCGs. A total of 77% of unsaturated fatty acids and low amounts of kahweol (7.09 µg/g) and cafestol (414.39 µg/g) were bioaccessible after in vitro digestion. A significantly lower (p < 0.1) accumulation of lipids in the liver and a higher excretion of these in feces was found in rats treated with SCGs for 28 days. No lipid droplets or liver damage were observed by histology. SCGs acutely accelerated intestinal motility in rats. SCGs might be considered a sustainable, safe, and healthy food ingredient with potential for preventing hepatic steatosis due to their effect as dietary fiber with a high fat-holding capacity.

4 October 2011 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
JGJosé M. García‐García
José M. García‐García
LLLaura LOPEZ-GÓMEZ
Laura LOPEZ-GÓMEZ
RPRodrigo París
Rodrigo París
MNMaría Teresa Núñez‐López
María Teresa Núñez‐López
Isabel QuijadaIsabel Quijada
Isabel Quijada
LGLeoncio Garrido
Leoncio Garrido